Induction of Cell Signaling Events by the Cholera Toxin B Subunit in Antigen-Presenting Cells

Cholera toxin (CT) is one of the most effective and widely studied mucosal adjuvants. Although the ADP-ribosylating A subunit has been implicated in augmenting immune responses, the receptor-binding B subunit (CT-B) has greater immunogenicity and may be a repository of adjuvant activity without pote...

Full description

Saved in:
Bibliographic Details
Published inInfection and Immunity Vol. 75; no. 6; pp. 3150 - 3159
Main Authors Schnitzler, Aletta C, Burke, Jennifer M, Wetzler, Lee M
Format Journal Article
LanguageEnglish
Published Washington, DC American Society for Microbiology 01.06.2007
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cholera toxin (CT) is one of the most effective and widely studied mucosal adjuvants. Although the ADP-ribosylating A subunit has been implicated in augmenting immune responses, the receptor-binding B subunit (CT-B) has greater immunogenicity and may be a repository of adjuvant activity without potential toxicity. In order to elucidate mechanisms of immune modulation by CT-B alone, primary B cells and macrophages were assessed for responses to CT-B in vitro, as measured by the expression of cell surface markers, cellular signaling events, and cytokine secretion. Increased phosphorylation of multiple signaling molecules, including Erk1/2 and p38, was detected. CT-B also induced transactivation of the transcription elements cyclic AMP-responsive element and NF-κB, the latter of which was inhibited by phosphotyrosine inhibition. While specific inhibition of MEK1/2 did not reduce CT-B induction of cell surface marker expression, it did attenuate CT-B-mediated interleukin-6 secretion. These data show that CT-B induces a set of signaling events related to cellular activation, surface molecule expression, and cytokine production that has potential implications for elucidating CT-B adjuvant activity in the absence of enzymatically active holotoxin.
Bibliography:http://iai.asm.org/
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Editor: J. L. Flynn
Corresponding author. Mailing address: Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Rm 638, Boston, MA 02118. Phone: (617) 414-4394. Fax: (617) 414-5280. E-mail: lwetzler@bu.edu
ISSN:0019-9567
1098-5522
DOI:10.1128/IAI.00581-06